We are live on ! Find out more
CATX icon

Perspective Therapeutics

26 hedge funds and large institutions have $2.36M invested in Perspective Therapeutics in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 3

0.09% less ownership

Funds ownership: 0.81%0.73% (-0.09%)

9% less capital invested

Capital invested by funds: $2.6M → $2.36M (-$242K)

13% less funds holding

Funds holding: 3026 (-4)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
26
Holders Change
-4
Holders Change %
-13.33%
% of All Funds
0.65%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
4
Reduced
3
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
VKH
26
Virtu KCG Holdings
New York
-$53K -9,116 Closed
PCM
27
Pointe Capital Management
Michigan
-$12.3K -2,129 Closed
UBS Group
28
UBS Group
Switzerland
-$117 -20 -23%

CATX Hedge Fund Activity: Q1 2017 in Review

26 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q1 2017, worth a combined $2.36M — down 9.3% from $2.6M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of CATX and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 4 added.

The largest buyer was BlackRock, opening a new position worth an estimated $559K. The largest seller was Anson Funds Management, exiting entirely with an estimated $235K sold.

  • 26 institutional investors held Perspective Therapeutics (CATX) as of Q1 2017, down from 30 in Q4 2016.
  • Funds reported $2.36M of Perspective Therapeutics stock for Q1 2017, down 9.3% quarter-over-quarter.
  • 2 funds opened new Perspective Therapeutics positions in Q1 2017 and 3 closed out, a net change of -1 holder.
  • The largest Perspective Therapeutics buyer in Q1 2017 was BlackRock, an estimated $559K added.
  • The largest Perspective Therapeutics seller in Q1 2017 was Anson Funds Management, an estimated $235K sold.

Based on aggregated 13F filings for Q1 2017.